Statement on senator Durbin’s bill

Biopharmaceutical Research Company (BRC) praised the latest congressional effort to increase access to federally compliant, American-grown cannabis strictly for use by researchers. A bill introduced today by Senator Dick Durban (D-IL) would transition cannabis from Schedule I to Schedule III under the Controlled Substances Act and provide research objectives to federal science and health agencies. Read more →